Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme commits to drugs price freeze

Merck Sharpe and Dohme commits to drugs price freeze

7th May 2010

Merck Sharpe and Dohme (MSD) has announced its commitment to a series of initiatives related to AIDS drug assistance programmes (ADAP) in the US.

As the main part of the agreement, the company has decided to extend the current price freeze for its Isentress and Crixivan products until the end of 2013.

Crixivan capsules have been at the same price level since 2003, while the cost of Isentress has not changed since 2008.

MSD will also work alongside the ADAP Crisis Task Force to provide “expanded financial relief” to relevant programmes which require increased discounts when purchasing the drugs.

Dwayne Haught, a spokesman for the task force, said: “We applaud Merck for its continued commitment to HIV [treatments].”

Earlier this week, MSD announced its results for the first three months of 2010.

The first quarter of the year saw the company record worldwide sales of $11.4 billion (7.76 billion pounds) and net income of $299 million.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.